Journal article
Management of Histoplasmosis by Infectious Disease Physicians
Open forum infectious diseases, Vol.9(7), pp.ofac313-ofac313
07/04/2022
DOI: 10.1093/ofid/ofac313
PMCID: PMC9310261
PMID: 35899286
Abstract
Histoplasmosis remains common along the Mississippi and Ohio river valleys, though 27% of infectious disease physicians reported seeing histoplasmosis outside these endemic areas. Variability of management strategy is increased for scenarios where guidelines lack strong recommendations, particularly for immunocompromised patients.
Background The Infectious Diseases Society of America (IDSA) guidelines for the management of histoplasmosis were last revised 15 years ago. Since those guidelines were compiled, new antifungal treatment options have been developed. Furthermore, the ongoing development of immunomodulatory therapies has increased the population at increased risk to develop histoplasmosis. Methods An electronic survey about the management practices of histoplasmosis was distributed to the adult infectious disease (ID) physician members of the IDSA's Emerging Infections Network. Results The survey response rate was 37% (551/1477). Only 46% (253/551) of respondents reported seeing patients with histoplasmosis. Regions considered endemic had 82% (158/193) of physicians report seeing patients with histoplasmosis compared to 27% (95/358) of physicians in regions not classically considered endemic (P < 0.001). Most ID physicians follow IDSA treatment guidelines recommending itraconazole for acute pulmonary (189/253 [75%]), mild-moderate disseminated (189/253 [75%]), and as step-down therapy for severe disseminated histoplasmosis with (232/253 [92%]) and without (145/253 [57%]) central nervous system involvement. There were no consensus recommendations observed for survey questions regarding immunocompromised patients. Conclusions Though there are increased reports of histoplasmosis diagnoses outside regions classically considered endemic, a majority of ID physicians reported not seeing patients with histoplasmosis. Most respondents reported adherence to IDSA guidelines recommending itraconazole in each clinical situation. New histoplasmosis guidelines need to reflect the growing need for updated general guidance, particularly for immunocompromised populations.
Details
- Title: Subtitle
- Management of Histoplasmosis by Infectious Disease Physicians
- Creators
- Patrick B. Mazi - Washington University in St. LouisSandra R. Arnold - Le Bonheur Children's HospitalJohn W. Baddley - University of Maryland, BaltimoreNathan C. Bahr - University of KansasSusan E. Beekmann - University of IowaTodd P. McCarty - University of Alabama at BirminghamPhilip M. Polgreen - University of IowaAdriana M. Rauseo - Washington University in St. LouisAndrej Spec - Washington University in St. Louis
- Resource Type
- Journal article
- Publication Details
- Open forum infectious diseases, Vol.9(7), pp.ofac313-ofac313
- DOI
- 10.1093/ofid/ofac313
- PMID
- 35899286
- PMCID
- PMC9310261
- NLM abbreviation
- Open Forum Infect Dis
- ISSN
- 2328-8957
- eISSN
- 2328-8957
- Publisher
- Oxford University Press
- Number of pages
- 6
- Grant note
- 21NU50CK000574 / CDC; United States Department of Health & Human Services; Centers for Disease Control & Prevention - USA K23 NS110470 / National Institute of Neurological Disorders and Stroke of the NIH UL1 TR002345 / Washington University Institute of Clinical and Translational Sciences through the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH)
- Language
- English
- Date published
- 07/04/2022
- Academic Unit
- Infectious Diseases; Epidemiology; Injury Prevention Research Center; Internal Medicine
- Record Identifier
- 9984359879002771
Metrics
16 Record Views